Thermo Fisher Scientific to Support National Program to Accelerate SARS-CoV-2 Variant Identification

CARLSBAD, Calif., (March 23, 2022) Thermo Fisher Scientific Inc., the world leader in serving science, today announced its collaboration with the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) Initiative, Helix, and Rosalind aimed at developing a new genotyping method for SARS-CoV-2 that could speed up the identification of variants as they emerge.
 

Utilizing a Polymerase Chain Reaction (PCR)-based genotyping approach that can be implemented in any testing lab performing real-time PCR, this program allows for a significant scale up of SARS-CoV-2 surveillance efforts in the United States. Data generated from this program will be available to the public through the Rosalind Tracker website. This effort was funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) as part of the NIH RADx Initiative to increase testing capacity and accessibility for the virus that causes COVID-19.
 

The rapid emergence of new SARS-CoV-2 variants raises several important public health questions, such as their ability to cause disease and their impact on vaccine efficacy. This makes it critical to track variants to better understand transmission patterns and possible consequences on health care resources. Next-Generation Sequencing (NGS) is the conventional method for detecting and tracing new variants, with about 5 percent of randomly selected SARS-CoV-2 positive samples in the United States being sent for variant identification. NGS, however, can possibly take up to 21 days from a positive result before variant data is available in public repositories.
 

With the addition of genotyping, labs can classify a high percentage of positive samples and provide information within two to three days. They can also reduce costs for strain subtyping as compared to NGS. Samples that cannot be assigned to a known variant through the genotyping approach become prime candidates to detect new or emerging variants more rapidly. 
 

“As COVID-19 evolves with new variants constantly emerging, surveillance will play a critical role as we learn to live with the virus,” said Dr. Manoj Gandhi, senior medical director of genetic testing solutions, Thermo Fisher.
 

“Our approach makes it possible to conduct surveillance testing on a significantly larger number of samples and quickly determine which variant is present in a sample,” said Dr. Eric Lai, co-lead investigator of the NIH RADx initiative. “If we start seeing a trend where we are unable to assign lineages using known markers in the genotyping assays, it is an early warning that a new variant may be emerging and helps determine which samples should be sent for sequencing. This is significant because emerging variants have the potential to evade vaccines, cause diagnostic test performance issues, or cause more severe disease.”
 

A recent paper outlines the performance of this method for identifying markers and assigning lineages to several SARS-CoV-2 variants, including previously characterized Variants of Concern (VOC) such as Alpha, Beta, Gamma and Delta. In addition, the study describes how this approach can be rapidly adapted to develop a targeted panel for currently circulating strains, such as Delta and Omicron, to allow for large-scale surveillance in routine testing laboratories.
 

The rapid selection and validation of highly sensitive and specific biomarkers for SARS-CoV-2 variants was enabled with the ROSALIND platform during the collaborative initiative. This dynamic, cloud-based data analytics platform was able to act as a centralized tool for labs by aggregating and analyzing the data in a real-time dashboard format. Thermo Fisher has updated the TaqMan SARS-CoV-2 Mutation Panel* to include the four markers that can detect the Omicron and Delta variants with high precision. 
 

“Our challenge has been staying in front of this pandemic at the rate the virus is evolving. We’ve demonstrated an approach for maintaining highly accurate markers, rapidly implementing marker updates in manufacturing, and quickly deploying these assays to nationwide testing labs for validating COVID-19 positivity with lineage assignment,” said Tim Wesselman, CEO of Rosalind. “With a public tracking dashboard, this automated analysis, classification, and real-time genotyping reporting provides a snapshot of the most current strains circulating the country and provide us with valuable information to respond more quickly.”
 

“A robust early warning surveillance capability will eventually incorporate multiple layers of novel technologies,” said Dr. David Becker, vice president of quality at Helix and co-investigator of the program. “We were excited to explore, understand, and validate this technology that enables rapid reporting and increased surveillance of the SARS-CoV-2 variants in circulation.”
 

*For research use only. Not for use in diagnostic procedures.


About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Owens & Minor completes acquisition of Apria, Inc.

March 29, 2022 – Owens & Minor has closed the previously announced acquisition of Apria, Inc. The acquisition was consummated for total consideration in cash of approximately $1.6 billion. The purchase was funded with a combination of debt and cash on hand. 

The transaction combines the strength of Owens & Minor’s existing Byram Healthcare business with Apria to create an enhanced experience for the patient, provider and payor. The combined entity will create: 

  • One of the broadest portfolios of complementary products to service patients with chronic and non-chronic conditions 
  • An expanded product delivery and distribution model 

Apria will be combined with Owens & Minor’s existing Byram Healthcare business to form the new Patient Direct segment. This new segment creates a robust commercial team with greater access to patients across a wider geographic footprint. It also expands Owens & Minor’s home healthcare portfolio to cover an unmatched range of chronic and acute care needs including diabetes, ostomy, incontinence, wound care, home respiratory, obstructive sleep apnea and negative pressure wound therapy. The company will leverage its existing market reach and expertise in the hospital setting to create a more efficient, single-source home healthcare delivery and distribution model to support patients as their care transitions from the hospital into the home. 

Daniel J. Starck, who has served as Chief Executive Officer for Apria since 2015, has joined Owens & Minor and will lead the new Patient Direct segment. 

“We look forward to unleashing the full potential of our teammates in the new Patient Direct segment to achieve even better clinical connectivity between the patient, the provider and the payor,” said Daniel J. Starck, Executive Vice President, President-Patient Direct, Owens & Minor. 

Beginning in the first quarter of 2022, Owens & Minor will change its reporting structure to reflect the company’s go-to-market approach. The two legacy segments will be replaced with two new segments: Patient Direct and Products & Healthcare Services. Patient Direct will be a combination of Byram and Apria, while Products & Healthcare Services will be a combination of the global products, medical distribution and services businesses. The company will release a historical recast for 2021, by quarter, ahead of reporting first quarter 2022 earnings. 

Learn More 

Filed Under: Repertoire’s Dail-eNews

Inflation and the healthcare supply chain: What you need to know

There’s no getting around it. Inflation has permeated every aspect of the economy – including the healthcare supply chain. Raw materials, energy, labor and logistics have all been affected, said Margaret Steele, Vizient Senior Vice President, Med/Surg.  

Indeed, over the 12 months from February 2021 to February 2022, the Consumer Price Index, which measures the average prices of consumer goods and services, increased 7.9% to a four-decade high.  

Labor costs rose 4% to 8% with manufacturers and freight companies struggling to attract workers and drivers. In the healthcare sector, escalating labor costs have been particularly painful. In its February National Hospital Flash Report, Kaufman Hall found that from December to January labor expense per adjusted discharge climbed 14.6%. 

Through the last year and a half (since fall 2020) energy, resins, cotton and most metals have all surged in excess of 30%. “With the recent upturn of oil prices, the rate of inflation will continue this upward trend,” Steele said. “These levels of inflation are impacting manufacturers and service providers significantly and they have begun raising prices on the supplies, equipment, and services they deliver to hospitals.” 

Global events hit home 

Steele said the healthcare supply chain has been significantly impacted over the last several years due to many factors including world events. As a result, timely and accurate information is critical to minimize impact and determine risk mitigation strategies.  

“Supply chain leaders use various tools, such as budget impact projection reports, market supply updates and category specific insights, to understand the impact of changes affecting raw materials, labor and logistics as they look to understand cost and risk for supply disruption,” Steele said. Now, supply chain leaders are utilizing these same sources to monitor the impact of the recent events that also have an impact on raw materials, manufacturing and transportation.  

Steele projects the most impactful and of most interest will likely be oil as so many products contain some form of plastic or resin (a derivative of oil). In mid-March, resin prices remained higher than pre-COVID levels and were expected to remain so as long as oil remains near or above $80 per barrel and producers continue struggling to get resins moved through the supply chain. Both issues are anticipated to remain through most of 2023. Oil price fluctuation, trucker shortages and port backups will also impact the costs for transporting products to the provider locations.  

“Many products have not yet been impacted as the situation is affecting raw materials,” Steele said. “That said, impact mitigation strategies vary by location and provider type. Providers are sharing conservation strategies in efforts to reduce usage as appropriate, pre-qualifying alternative products in the event of a disruption, increasing product on hand (or at a distributor/partner location) and ensuring product is sourced from a variety of locations. Several suppliers have medical teams that will work with the providers directly to discuss alternative uses. And, many are also participating in commitment programs, wherein suppliers and providers agree on a longer, committed supply and in some cases pricing.” 

While GPO and self-negotiated contracts are keeping prices fairly stable at the moment, supply chain leaders fully expect to see significant price increases in the next series of contracts, said Mike Schiller, senior director of supply chain at the Association for Health Care Resource & Materials Management (AHRMM) of the American Hospital Association (AHA).  

“Many are anticipating high single to low double digit price increases and have begun to include these into their budgetary considerations.” 

Filed Under: Repertoire’s Dail-eNews

Thermo Fisher Scientific RT-LAMP Tests Simplify Infectious Disease Surveillance

Low-cost kits help global public health professionals quickly identify potential outbreaks

CARLSBAD, Calif., March 9, 2022 – To support active research and surveillance of viral pathogens, including SARS-CoV-2, Thermo Fisher Scientific has launched two new reverse transcription loop-mediated isothermal amplification (RT-LAMP)-based solutions. While PCR remains the gold standard for diagnostic, lab-based testing, isothermal RT-LAMP nucleic-acid-based amplification provides a rapid and low-cost option for viral pathogen detection.

“In the global fight against COVID-19 and future infectious disease outbreaks, researchers need cost-effective, easy-to-use solutions for rapid detection of viral pathogens,” said Dale Patterson, vice president and general manager of molecular biology at Thermo Fisher Scientific. “With RT-LAMP technology, researchers can accurately detect the presence of a pathogen by seeing a simple color change with the naked eye. Our new solutions enable frequent – even daily – surveillance without complex instrumentation or highly trained staff, making them ideal tools to support community surveillance in resource-constrained areas.”

The Invitrogen Colorimetric ReadiLAMP Kit, SARS-CoV-2* is an off-the-shelf assay designed to provide accurate, robust detection of SARS-CoV-2 from saliva, nasal or nasopharyngeal swab samples. The kit includes two protocols: a rapid, 30-minute turnaround time for crude sample types, which reduces reagents use and costs by eliminating the need for nucleic acid isolation, or a one-hour turnaround time for increased sensitivity with purified RNA sample types.

“Thermo Fisher is committed to expanding access to solutions to aid global SARS-CoV-2 surveillance efforts as the world continues to monitor for new variants,” said Ellie Mahjubi, vice president and general manager of sample preparation at Thermo Fisher Scientific. “For instance, we have introduced modified workflows that use room-temperate stable reagents to eliminate the need for cold storage. We are also gathering data on pooling samples to provide a highly affordable option for reliable population-level infectious disease monitoring that could be easily deployed anywhere in the world, including in developing countries.”  

For infectious disease researchers looking to research or develop their own assays for a range of applications, the Invitrogen SuperScript IV RT-LAMP Master Mix* provides fast and sensitive detection of viral pathogens, including SARS-CoV-2, measles and influenza, in as little as five minutes. The optimized master mix uses robust enzymes and is compatible with multiple methods for evaluating results, offering the flexibility to optimize assay development for a variety of RNA and DNA targets and concentrations.

To learn more about the Colorimetric ReadiLAMP Kit and SuperScript IV RT-LAMP Master Mix, visit thermofisher.com/rtlamp.

*For research use only. Not for us in diagnostic procedures.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.


Media contact information:

Mauricio Minotta

760-805-5266

mauricio.minotta@thermofisher.com

Jen Heady

413-237-5141

jheady@greenough.biz


SOURCE Thermo Fisher Scientific

If you have any questions regarding this Press Release, please email us at media.relations@thermofisher.com.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.


Media contact information:

Mauricio Minotta

760-805-5266

mauricio.minotta@thermofisher.com

Jen Heady

413-237-5141

jheady@greenough.biz


SOURCE Thermo Fisher Scientific

If you have any questions regarding this Press Release, please email us at media.relations@thermofisher.com.


Mask mandates dropped in every state: 3 pandemic updates

Erica Carbajal

Hawaii Gov. David Ige on March 8 announced the state would lift its universal indoor mask mandate March 26, making it the final state to do so, The New York Times reports. 

“We have reduced COVID-19 in a way to the point where most of us will be safe without masks indoors,” Mr. Ige said during a press conference.

The move is an abrupt pivot from a week ago, when the governor said the mask mandate would remain in place as other restrictions, such as the state’s entry requirements for travelers, were dropped. Hawaii held onto its mask mandate longer than most of the country because “we are willing to sacrifice to keep each other healthy and safe,” Mr. Ige said. Masks will remain a requirement indoors at public schools in the state. 

The CDC on March 3 provided an update on its new mask guidance, saying more than 90 percent of the U.S. population now live in areas with low or medium COVID-19 community levels, indicating masks are not needed. 

Two more updates: 

1. In a reversal, the World Health Organization on March 8 expressed support for COVID-19 boosters shots. The organization’s Technical Advisory Group on COVID-19 Vaccine Composition said in a statement it “strongly supports urgent and broad access to current COVID-19 vaccines for primary series and booster doses, particularly for groups at risk of developing severe disease.” 

In August 2021, the WHO called for an international moratorium on booster doses as primary vaccination rates remained low in vulnerable countries. In its latest update, the agency said, “The near- and medium-term supply of the available vaccines has increased substantially; however, vaccine equity remains an important challenge and all efforts to address such inequities are strongly encouraged.” 

2. In a move “toward the endemic phase of the pandemic,” the Oklahoma State Department of Health is ending daily COVID-19 reports that provided updates on new cases, COVID-19 hospitalizations and death tolls. The state will now shift to a weekly report on Thursdays, according to a March 7 news release. The shift will allow the health department to “focus on key metrics that more accurately represent the impact of disease in the community, like hospitalizations.”

All the World’s a Stage

Pandemic proves that healthcare logistics demands a global perspective

By Mark Thill

A year ago, were you aware of the term “dwell time?” Did the word “container” connote anything other than Tupperware? Did you know how many weeks in a typical month an over-the-road trucker is away from home? Had you ever stopped at the Corwith Yards on the Southwest Side of Chicago to see what goes on at a railroad intermodal freight terminal?

How quickly would you have made the connection between a resin factory fire in Texas and the availability and price of medical products? How about a cold spell in the Lone Star State, a hurricane in Puerto Rico, a cargo ship stuck in the Suez Canal, a drought in Taiwan affecting microchip production, or a virus causing concern among authorities in a Chinese city named Wuhan?

Due to world events of the past 24 months, healthcare supply chain executives are finding that what they once took for granted, what they learned from the logistics gurus, doesn’t necessarily work during pandemics.

“PPE supply was the biggest challenge for 2020,” says Mark Henderson, senior vice president of sales and marketing for Concordance Healthcare Solutions. “The issues in 2021 have been much broader, as it is not just about aligning supply and demand, but rather the challenges related to getting product from the manufacturers to the distributors and providers. You can have an accurate picture of product needs and manufacturing volumes, but if you cannot get product from point A to point B in a timely fashion, you have an issue.”

Getting products from point A to point B ain’t what it used to be. The question is, will it ever return to “normal?” Based on comments gathered by Repertoire, even if we don’t see a full-blown paradigm shift, we will see changes, especially:

  • Advances in visibility – transparency – across the supply chain.
  • Creative ways to store products, such as 3PLs or what one distributor calls “living stockpiles.”
  • Increased attentiveness to alternative or substitute products, just in case.

The situation

“Things are more difficult now than at any other point in the pandemic,” Abby Pratt, senior vice president for global strategy and analysis for AdvaMed, the medical manufacturers association, told Repertoire in December. (The Advanced Medical Technology Association, or AdvaMed, represents companies that produce medical devices, diagnostic products and digital health technologies.) “In the early stages, it was limited to things like PPE and COVID technologies. But now, delays, bottlenecks and disruptions are making headlines, just as they are in every other sector. It’s not only affecting products and materials imported into the United States, but also raw materials, supplies and components that are coming into the U.S. for manufacturing and production in this country.”

James Sembrot, senior vice president, U.S. Supply Chain, Cardinal Health, says, “As an industry, the supply chain is facing increased global demand for product and movement of product, primarily from Asia-Pacific to the United States. Additionally, the supply chain is encountering container shortages, port congestion and operational constraints, vessel availability challenges, disruptions in shipping schedules and increased wait times, labor shortages and heightened shipping costs.”

Ocean freight delays and raw material inflation have caused significant constraints, adds Robert Rajalingam, president, U.S. Medical Products and Distribution, Cardinal Health. “Resins, corrugate and metals have experienced significant cost increases. Because of the winter storm impacts, and prior to that, the fire at the resin manufacturer, Total Petrochemicals, we’re dealing with a market that’s been constrained for well over a year.

“During a global pandemic environment and with many manufacturers on allocation, the challenges compound,” he says. “Plus, resin is not only used to form plastics, like sharps containers, but it is also used in non-woven fibers, tubing, flexible packaging, etc.”

Container costs have grown to eight times the normal rates, he says. Over a recent 12-month period, Cardinal Health spent $48 million on charters to bring in product from Asia. “But this system is not cost effective and not a long-term strategy.”

A crisis by any other name

“Part of the definition of ‘crisis’ is a time of great difficulty,” says Henderson. “Personally, I prefer to think of it as a tremendous challenge that we will need to resolve collaboratively across suppliers, distributors, providers, logistics organizations and state and local agencies. Any supply chain that has a patient at the end of it needs to be prioritized.”

The difference between 2020 and 2021? “I’m not sure I would call [the current situation] a crisis anymore, as it was in 2020,” says Steve Martin, senior vice president of supplier management for Nashville-based NDC Inc. “Product is moving. It’s just moving slower and at a much higher cost. Supply chain issues have negatively impacted our fill rates as we still have a significant number of products that continue to be on allocation or in short supply. Also, the increase in lead times from suppliers makes it difficult to quickly react to changes in product demand from our distributors.

“The rising cost of freight across all modes has significantly impacted the cost to serve suppliers, NDC and our distributors,” he continues. “We have seen unprecedented increases in product costs, sometimes appearing as an ‘order surcharge,’ which is directly related to the global and national supply chain issues.”

Supply chain and clinical professionals may not be using the word “crisis” to describe the current situation, but they are definitely in pandemic mode, says Mike Schiller, senior director of supply chain for the Association for Health Care Resource & Materials Management of the American Hospital Association. In addition to sourcing supplies through traditional channels, they are diversifying vendor portfolios and employing conservation and utilization strategies.

Two years into the pandemic, the industry has moved beyond PPE-only shortages to shortages in other business sectors that are directly or indirectly affecting the healthcare supply chain, he says. These include:

  • Semiconductors: As of late December, shortages were causing 9-to-12-month equipment delays.
  • Aluminum products (crutches, walkers, canes): In response, some organizations are seeking donations from the community.
  • Blood collection tubes: Varying, rolling backorders. Solutions and conservation strategies include using EMRs to view and manage orders, review blood draw requests.
  • Pediatric supplies (e.g., diapers, formula, nipples, small French urine collection catheters, butterfly needles and umbilical cord catheters, neonate blood pressure cuff size 4, cardiac leads). Solutions include purchasing individual components – urine specimen cups, sticks, wipes, etc. – and assembling kits, exploring reuse of disposable blood pressure cuffs or moving to reusable cuffs.
  • Resin products (e.g., suction canisters, sharps containers, soap containers, decontam wipes tubs, hand soap and foaming soap dispensers). Solutions include exploring reusable sharps containers.

Inflation is another concern, says Schiller. Although GPO and other contract pricing has remained relatively stable throughout the pandemic, supply chain professionals can expect increases due to supply/logistics demand and constraints, new supply and multisource contracts, and diversified vendor portfolios. “We are encouraging supply chain leaders and healthcare organizations to explore other non-labor cost-savings opportunities, with a key area being purchased services.”

Visibility

A common theme among supply chain executives is the need for greater visibility across the supply chain. But given the many constituencies involved – raw materials suppliers, factories, ocean carriers, railroads, trucking firms, med/surg distributors and health systems – that won’t be easy.

“Raising the bar on accuracy and visibility of data from suppliers is critical as we move forward,” says Henderson. “Combined with visibility to our on-hand inventories and demand signals from customers, we can move toward a proactive supply chain powered by actionable information. Automating this process … is key.”

In November, AdvaMed, the Health Industry Distributors Association (HIDA) and International Safety Equipment Association (ISEA) announced they were collaborating with port leaders to test processes for prioritizing medical supply containers. The organizations have engaged the Federal Maritime Commission and the White House Supply Chain Disruption Task Force in their efforts.

“But we have to approach it terminal operator by terminal operator, because they are not interoperable,” says Pratt. “There’s no single system spanning all these different actors. That’s why we are looking at greater interoperability and visibility.”

Curtis Lancaster, chief supply chain officer, Westchester Medical Center Health Network (WMCHealth), Valhalla, New York, says the health system’s supply chain team collaborates regularly with its clinicians and distribution partners, and uses AI-powered software to identify global trends that may affect the supply chain. “We also collaborate with onshore and near-shore partners that reduce our reliance on offshore suppliers,” he says. WMCHealth comprises 10 hospitals and includes an academic medical center, acute care children’s hospital, multiple community hospitals, skilled nursing facilities and two practices with over 850 providers.

Cardinal Health is making “significant investments in technology to drive greater visibility, sustainability and resiliency,” says Rajalingam. In March 2020, the company began working with freight-tracking software startup FourKites Inc. on a pilot to track shipments of personal protective equipment between manufacturing plants and the company’s distribution centers.

Centralized advanced planning data allows those in the supply chain to jointly conduct forecasting and supply chain simulations and plan alternative options, says Rajalingam. “It also drives network inventory optimization.

“Through extensive collaboration with leading 3PL organizations, we are expanding access to secure equipment (i.e., containers), capacity and alternative routes; increasing visibility to enable quick, data-backed decision-making; increasing visibility to the location of shipments across oceans, through ports, etc.; and managing supply chain costs.”

No paradigm shift on JIT

Choke points, logjams and bottlenecks notwithstanding, healthcare supply chain experts aren’t predicting a widespread about-face on just-in-time. “I don’t think you’ll see a paradigm shift,” says Pratt. “Companies will do more to invest in risk mitigation and might build these learnings into their processes, but when things normalize, they will want to be efficient.” That holds true for products that are perishable as well as those in which innovation occurs rapidly. “If you stockpile too much, you will have some obsolescence. So it’s a balance.”

Concordance Healthcare Solutions found 3PL storage to be in high demand during 2020 and into 2021, says Henderson. “Much of this was PPE products, but the service can apply across any category. We will continue to ramp up these programs for both providers and suppliers to increase access to products.”

Says Mike Schiller, “Just-In-Time, Low Unit of Measure and Lean principles will need to be re-evaluated across the entire supply chain continuum. COVID has highlighted our need for more transparency, robust analytics and improved utilization data – the capture of product use at the point of consumption.” Moving from par inventories to demand planning, where possible, may help achieve better alignment between on-hand inventory levels and actual use.

Solutions

Charlotte Perkins, interim vice president of supplier and portfolio management for Owens & Minor, says the company’s Americas-based manufacturing has helped maintain the supply of personal protective equipment throughout the pandemic. “We manufacture our own raw materials in North Carolina and convert them into N95 respirators, isolation gowns, surgical gowns, ear loop masks and other PPE in our plants in Texas, Mexico and Honduras.”

In addition to self-manufactured products, Owens & Minor partners with more than 1,000 branded manufacturers. “We have recently seen minor supply chain challenges with IV solutions and syringes, as well as a slight increase in demand for IV catheters,” says Perkins, adding that the company’s allocation practices have enabled it to fulfill demand even during the peak of the pandemic.

For more than 10 years, Owens & Minor has provided an outsourced logistics offering to help customers address pandemic storage requirements and to manage supply streams from multiple sources, she adds. In 2020, the company expanded this capability across the entire network, with more than 25 Owens & Minor distribution centers now actively delivering Outsourced Logistics services. In addition, Owens & Minor clients can now subscribe to alerts via the SMART Card (Supplier Metrics & Accountability Report Tracker) for bi-weekly snapshots and updates, keeping them aware of product constraints or supply chain disruptions.

Steve Martin says the NDC team has devised several solutions to help members maintain an adequate supply of products and equipment, including:

  • Distributor allocations based on historical demand or as directed by suppliers.
  • Lead time adjustments from suppliers to accommodate supply chain issues, sometimes increasing the amount of stocked inventory to account for longer lead times.
  • Careful review of new business opportunities on products that have longer lead times to protect NDC’s ability to service existing business from distributors.

“NDC doesn’t manage the inbound logistics of shipments from suppliers, which is managed by the suppliers themselves,” says Martin. “So it is important for us to be well informed of the status of inbound containers or shipments. Many suppliers have established regularly occurring calls with NDC to review the status of containers/shipments, update production lead times, review product allocations, and provide general business updates.”

Many NDC members have established multiple supplier relationships for impacted products, where possible, he adds. “Some members have begun sourcing more products directly from manufacturers to increase their control over product visibility and access. This includes looking at alternative ports of entry for products that source via ocean freight.

“Many NDC distributors are also working with their provider customers to encourage them to increase their safety stock on critical items. Some have expanded existing warehouse space and/or added warehouses in strategic geographical areas, so they can provide stockpile services to their provider customers.”

Cardinal Health’s Robert Rajalingam says that the company is actively lobbying Capitol Hill with other industry associations for resolution of the current backup of medical products. “We are also working with the federal government to prioritize releasing backlogged containers with critical medical supplies. Plus, we’ve had a high level of involvement with HIDA and AdvaMed, as well as the ports of Los Angeles and Long Beach and the Federal Maritime Commission, to structure a broad-based prioritization process for identifying and expediting critical medical supplies through the ports.”

Says AHRMM’s Mike Schiller, “Moving forward, successful supply chain professionals will need to possess a global acumen, understanding how disruptions, like raw material shortages, labor, political unrest, etc., may impact their supply chains. They will need to remain strategic and reduce or eliminate risk from their supply chains through deeper collaboration with existing suppliers while looking to build relationships with local and community businesses.”

Funding to support primary care residents in rural and underserved communities

February 16, 2022 – Earlier this month, the U.S. Department of Health and Human Services (HHS), through the Health Resources and Services Administration (HRSA), announced the availability of $19.2 million in American Rescue Plan funding to support and expand community-based primary care residency programs. Awardees will use this funding to train residents to provide quality care to diverse populations and communities, particularly in underserved and rural areas.  

The Teaching Health Center Graduate Medical Education (THCGME) program supports training in community-based care settings. These training sites offer primary care and dental residents experience working with diverse, high-need patient communities in areas that often lack sufficient primary care physicians and dentists, according to a release. After completing residencies, the majority of THCGME program graduates will continue to practice in underserved or rural settings and two-thirds continue to practice primary care – nearly double the average of all medical and dental graduates. 

“Training physician and dental residents in community settings is helping us to build a stronger primary care workforce that better supports the communities served,” said HRSA Administrator Carole Johnson. “The American Rescue Plan funding announced today will help us to grow the number of primary care residents training and practicing in underserved communities, a critical step toward expanding access to high-quality health care and advancing health equity.” 

This THCGME funding opportunity will increase the program’s reach and support the equivalent of approximately 120 full-time resident positions. Teaching Health Center primary care residency programs offer training in skills needed to care for populations such as members of tribal communities, residents of rural areas, and people who are medically underserved. 

Funding to support primary care residents in rural and underserved communities – The Journal of Healthcare Contracting (jhconline.com)

Owens & Minor, Inc. Signs Definitive Agreement to Acquire Apria, Inc.

January 10, 2022 – Owens & Minor, Inc. (Owens & Minor) and Apria, Inc. (Apria) announced that the companies have entered into a definitive agreement pursuant to which Owens & Minor will acquire Apria for $37.50 in cash per share of common stock, representing an equity value of approximately $1.45 billion. 

“I’m very excited about the acquisition of Apria, which will strengthen our total company value proposition. The combination of two complementary businesses in Byram Healthcare and Apria will enable us to better serve the entire patient journey – through the hospital and into the home – ultimately furthering our mission of Empowering Our Customers to Advance Healthcare,” said Edward A. Pesicka, President & Chief Executive Officer of Owens & Minor. “In addition, this transaction diversifies our total company revenue stream by expanding our presence in the higher-growth home healthcare market.” 

“I am energized and enthusiastic to join Owens & Minor,” said Dan Starck, Chief Executive Officer of Apria. “Both companies share cultures fueled by a commitment to customers, patients, teammates and the communities we serve. We look forward to joining together and delivering the highest quality healthcare solutions to our customers.” 

Owen & Minor’s Strategic Rationale

  • Strengthens total company value proposition, enables Owens & Minor to better serve the entire patient journey and positions Owens & Minor as a leader in the home healthcare market. The transaction builds upon Owens & Minor’s strong capabilities in product manufacturing and healthcare services. 
  • Accelerates growth and diversifies revenue base by expanding Owens & Minor’s presence in the higher-growth home healthcare market. 
  • Accretive to revenue, adjusted EBITDA, adjusted earnings per share, and enhances the free cash flow generation, enabling Owens & Minor to rapidly deleverage while continuing to invest across the business. 
  • Expands the Patient Direct platform with access to over 90 percent of insured healthcare customers in the U.S. 
  • Broadens the Patient Direct product portfolio by combining our strength in diabetes, ostomy, incontinence, and wound care, with Apria’s product portfolio strength in home respiratory, obstructive sleep apnea, and negative pressure wound therapy. These product portfolios are complementary and do not overlap as many of these products are needed to treat the same and multiple chronic and acute conditions. 
  • Increases the attractiveness to Payors, Providers, and Patients due to the broader product portfolio, combined with our scale, geographic footprint, and delivery model. 
  • Creates a platform for future growth within this highly fragmented and growing space, with an approximate $50 billion total addressable market. 
  • Enables the acceleration of support for the hospital customers seeking to expand into home healthcare delivery. 

Learn More 

Filed Under: Repertoire’s Dail-eNews

Thermo Fisher Scientific Completes Acquisition of PeproTech, a Leader in Recombinant Proteins therapy market

Increases capabilities serving the high growth cell and gene therapy market

WALTHAM, Mass., Jan. 5, 2022 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and PeproTech, Inc., a leading developer and manufacturer of recombinant proteins, today announced that Thermo Fisher completed its acquisition of PeproTech on December 30, 2021 for a total cash purchase price of approximately $1.85 billion.

Based in Cranbury, New Jersey, PeproTech is a privately held provider of bioscience reagents known as recombinant proteins, including cytokines and growth factors. Recombinant proteins are used in the development and manufacturing of cell and gene therapies as well as in broader cell culture applications, especially for use in cellular research models. PeproTech’s recombinant proteins portfolio complements Thermo Fisher’s cell culture media products and will enable Thermo Fisher to provide customers significant benefits through an integrated offering.

“PeproTech will be an excellent strategic fit within our biosciences business and will allow us to even better serve our pharma and biotech customers by adding new capabilities to our existing offering,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “In combination with our proprietary bioprocessing and cell culture technologies, this complementary transaction positions us to partner with our customers to drive the evolution of the fast-growing market for cell and gene therapies. By leveraging our commercial reach, we will be able to efficiently grow the PeproTech business and generate attractive financial results all while furthering our Mission to enable our customers to make the world healthier, cleaner and safer.”

Casper added, “With more than three decades of experience across a broad range of applications for drug development and therapeutic products, the PeproTech team has built long-standing customer relationships in pharma and biotech and life sciences research. We look forward to welcoming their incredibly talented team to Thermo Fisher.”

Bob Goldman, president and co-founder of PeproTech, commented, “We are pleased to join Thermo Fisher given their team’s outstanding industry leadership and shared commitment to develop innovative therapies that improve patient outcomes. PeproTech’s reputation for unparalleled product consistency and quality directly aligns with that of Thermo Fisher’s, and we look forward to building on our success as part of the world leader in serving science.”

PeproTech will become part of the biosciences business within Thermo Fisher and will be integrated into the Life Sciences Solutions Segment.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team of more than 100,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

About PeproTech

PeproTech, Inc., a New Jersey corporation that was incorporated in 1988, creates the building blocks of life science research by manufacturing high-quality products that advance scientific discovery and human health. Our business is heavily weighted towards the development, manufacture and sale of research-use only and GMP cytokines and other products that support and address the needs and demands of today’s scientists and researchers.

Safe Harbor Statement

The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the duration and severity of the COVID-19 pandemic; the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers’ capital spending policies and government funding policies; the effect of economic and political conditions and exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; any natural disaster, public health crisis or other catastrophic event; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in our most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, which are on file with the SEC and available in the “Investors” section of our website under the heading “SEC Filings.” While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.

Media Contact Information:
Ron O’Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com

Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com

SOURCE Thermo Fisher Scientific

If you have any questions regarding this Press Release, please email us at media.relations@thermofisher.com.

Health systems suspend vaccine mandate after CMS suspends ruling

December 7, 2021 – CMS in a Dec. 2 memorandum suspended implementation and enforcement of its COVID-19 vaccination mandate for healthcare workers after judges in Missouri and Louisiana issued preliminary injunctions temporarily halting the start of the COVID-19 vaccination mandate.

An injunction issued Nov. 30 by a federal judge in Louisiana temporarily blocks CMS from enforcing its vaccination mandate for healthcare workers until legal challenges are resolved.

The injunction effectively expanded a separate order issued Nov. 29 by a federal judge in Missouri that temporarily halted the mandate in 10 states.

In light of the legal challenges, hospitals and health systems have made new decisions, including suspending their requirements.

Since the announcement, several healthcare organizations have announced they are suspending their mandates or extending the deadlines for employees. Here are a few:

  • AdventHealth announced Dec. 2 that it was suspending all vaccination requirements of it’s COVID-19 vaccination policy. The health system is still requiring employees to declare their COVID-19 vaccination status with their medical staff office.
  • HCA announced on Dec. 1 that the organization would “pause the COVID-19 vaccine requirement for all Medical City Healthcare colleagues.”
  • Cleveland Clinic announced Dec. 2 that it is pausing the implementation of the health system’s vaccination policy, which required employees and those who provide services with the health system to receive the vaccine or an approved exemption with accommodations. The health system said it will have additional safety requirements for unvaccinated workers, including periodic testing for those providing direct clinical care. 
  • Tenet Healthcare (Dallas, TX) also said it will not enforce the CMS vaccination requirement for individuals working in its facilities. Tenet said workers who are in a state that has previously issued a vaccination mandate must continue to follow the state or local requirement.
  • Hospital Sisters Health System (Springfield, IL) announced Dec. 3 that it is keeping its newly established vaccination policy in place while courts review the federal rule for healthcare workers. The health system is extending the vaccination deadline from Dec. 6 to Jan. 31.
  • Kootenai Health (Coeur d’Alene, ID) is also delaying the effective date of its vaccination requirement from Dec. 6 to Dec. 13

Health systems suspend vaccine mandate after CMS suspends ruling – The Journal of Healthcare Contracting (jhconline.com)